Decoy Files $50M Shelf While Carrying Going-Concern Warning and Nasdaq Delisting Risk
DCOY is trading near its 52-week low of $0.9 (8.4% above the low).
Summary
Decoy Therapeutics filed a $50 million universal shelf registration, giving it capacity to sell securities from time to time — no shares sold yet. The filing lands while the company carries a going-concern warning, cash runway only into early 2027, and active Nasdaq delisting risk.
Key Events · Financing and Capital Events · DCOY
-
New $50M Universal Shelf Filed
A Form S-3 registers up to $50,000,000 of common stock, preferred stock, warrants, debt securities and units for sale from time to time. No securities have been sold under it; each tranche requires a prospectus supplement.
-
Float Caps Practical Raise
Public float is approximately $2,525,022 based on 2,385,282 shares outstanding, of which only 68,748 are held by non-affiliates. Under General Instruction I.B.6, primary sales are limited to one-third of float in any 12-month period while float stays below $75 million.
-
Going-Concern Warning Restated
Substantial doubt about the ability to continue as a going concern is stated in the filing, with existing cash and equivalents sufficient to fund operations only into early 2027.
-
Nasdaq Delisting Overhang
A Mandatory Panel Monitor through March 31, 2027 applies to the company, and the stayed $5 million MVLS Rule could, if approved, delist the stock with no compliance or cure period.
Analysis · DCOY · Life Sciences
Decoy has registered the capacity to sell up to $50 million of stock, preferred, warrants, debt or units from time to time — no shares have been sold, and each actual tranche needs its own prospectus supplement. That headline size dwarfs the company itself: with a public float of roughly $2.5 million and only 68,748 shares held by non-affiliates, General Instruction I.B.6 caps primary sales at one-third of float in any 12-month window, so the practical raise is a small fraction of the stated amount. What lifts this above a routine shelf is the backdrop the filing restates — substantial doubt about the ability to continue as a going concern, cash said to last only into early 2027, a Nasdaq Mandatory Panel Monitor running through March 31, 2027, and a stayed $5 million market-value listing rule that, if approved, could delist the stock with no cure period. Any drawdown on this shelf will be heavily dilutive to a very thin float, and the company needs capital to keep operating.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DCOY was trading at $0.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.90 to $16.92. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.